- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Retrospective, Multicentre
- Objective: To analyse first-line COVID-19 combination regimens for virological and clinical outcomes and safety in a large cohort of immunocompromised_x000D_ patients
- Number of participants enrolled: 144
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
- Molnupiravir
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
External Links
Other information
Funders/Sponsors:
- Projekt DEAL
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to